Plant-based diet study for MGUS or smoldering myeloma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of MGUS or smoldering multiple myeloma (SMM)
- You are at least 18 years old and can follow study instructions
- You can do normal daily activities (about self-care possible; your doctor rates this as ECOG 0 to 3)
- You want to learn and follow plant-based cooking recipes
- You do not already follow a whole-food plant-based diet day to day
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a plant-based diet and certain supplements can help people with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). Participants will learn to cook plant-based recipes and track their meals using a phone app.
This study tests whether a Korean-style Mediterranean diet and tracking physical activity can help people with MGUS or smoldering multiple myeloma. Participants will follow the diet for 12 weeks and wear a device to measure their daily activity.
This study tests whether a special diet—longer nightly fasting plus a Mediterranean eating pattern—can help people with multiple myeloma or its early stages. If you qualify, you will be randomly assigned to start the diet right away or join a waitlist group.
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
This trial watches people with a high-risk form of smoldering myeloma (an early, inactive stage of bone marrow cancer) to learn more about how it changes. It may help doctors know who needs treatment later.
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
Hear when a new Monoclonal Gammopathy of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.